In particular, combined anti-PD-1 and anti-CTLA-4 treatment exhibits greater response rates than monotherapy of either agent in melanoma48, lung cancer49, and colon cancer50, albeit at the cost of greater immune-related adverse effects51. Here, PDCD1 is linked to digestive system cancer.